Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  2011-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1365-2125.2011.03936.xPMID 21306419PMCID PMC3099375
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects

  2010cited by this paper
• Pharmacokinetics, pharmacodynamics and the pharmacokinetic/ pharmacodynamic relationship of zolpidem in healthy subjects

  2010cited by this paper
• The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects

  2010cited by this paper
• Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol

  2010cited by this paper
• Modelling of the concentration—effect relationship of THC on central nervous system parameters and heart rate — insight into its mechanisms of action and a tool for clinical research and development of cannabinoids

  2008cited by this paper
• Effect of intrapulmonary tetrahydrocannabinol administration in humans

  2008cited by this paper
• Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABAA α2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers

  2008cited by this paper
• Pharmacodynamic and pharmacokinetic effects of TPA023, a GABAA α2,3 subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers

  2007cited by this paper
• Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.

  2007cited by this paper
• Effects of acute doses of oxiracetam in the scopolamine model of human amnesia

  2005cited by this paper
• Muscarinic and nicotinic receptor modulation of object and spatial n-back working memory in humans.

  2005cited by this paper
• Caffeine attenuates scopolamine-induced memory impairment in humans

  2005cited by this paper
• Pharmacokinetics and Pharmacodynamics in Clinical Use of Scopolamine

  2005cited by this paper
• Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.

  2005cited by this paper
• Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood

  2005cited by this paper
• The Application of the Principles of Clinical Drug Development to Pharmacological Challenge Tests of the Serotonergic System

  2004cited by this paper
• Pharmacokinetic/pharmacodynamic Assessment of Tolerance to Central Nervous System Effects of a 3 mg Sustained Release Tablet of Rilmenidine in Hypertensive Patients

  2004cited by this paper
• Estimation of pupil size by digital photography

  2004cited by this paper
• Qualitative analysis of scopolamine-induced amnesia

  2004cited by this paper
• Dose-specific effects of scopolamine on canine cognition: Impairment of visuospatial memory, but not visuospatial discrimination

  2004cited by this paper
• Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

  2003cited by this paper
• A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population.

  2003cited by this paper
• Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes.

  2003cited by this paper
• Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects.

  2003cited by this paper
• Pharmacokinetic‐Pharmacodynamic Modeling of the Electroencephalogram Effects of Scopolamine in Healthy Volunteers

  2001cited by this paper
• Studies of Interference in Serial Verbal Reactions

  2001cited by this paper
• The sensitivity of pharmacodynamic tests for the central nervous system effects of drugs on the effects of sleep deprivation

  1999cited by this paper
• Pharmacokinetics and Pharmacodynamics of Scopolamine after Subcutaneous Administration

  1998cited by this paper
• Scopolamine model of dementia: electroencephalogram findings and cognitive performance

  1998cited by this paper
• Cognitive and Behavioral Effects of Cholinergic, Dopaminergic, and Serotonergic Blockade in Humans

  1997cited by this paper
• Minimal effects of dextroamphetamine on scopolamine-induced cognitive impairments in humans.

  1997cited by this paper
• Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling.

  1997cited by this paper
• Connection of pharmacokinetics and pharmacodynamics--how does it work?

  1997cited by this paper
• Physostigmine Reversal of Scopolamine-Induced Hypofrontality

  1997cited by this paper
• The effects of a benzodiazepine receptor antagonist β-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills

  1996cited by this paper
• Cognition Enhancers in Age-Related Cognitive Decline

  1996cited by this paper
• Pharmacodynamic and early clinical studies with velnacrine

  1993cited by this paper
• In vivo Muscarinic Cholingeric Receptor Imaging in Human Brain with [11C]Scopolamine and Positron Emission Tomography

  1992cited by this paper
• Cholinergic 'blockade' as a model of the cognitive deficits in Alzheimer's disease.

  1992cited by this paper
• In vivo muscarinic cholinergic receptor imaging in human brain with [11C]scopolamine and positron emission tomography.

  1992cited by this paper
• Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model.

  1992cited by this paper
• A comparison of the sensitivities of adaptive tracking, eye movement analysis, and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers

  1991cited by this paper
• Effects of NMDA Modulation in Scopolamine Dementia a

  1991cited by this paper
• Group Report 3: Early Clinical Testing of Cognition Enhancers: Prediction of Efficacy

  1990cited by this paper
• Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls

  1990cited by this paper
• The effects of 0.025% hyoscine hydrobromide eyedrops on visual function in man

  1989cited by this paper
• Modelling dementia: effects of scopolamine on memory and attention.

  1988cited by this paper
• Complex dose-response curves of atropine in man explained by different functions of M1- and M2-cholinoceptors

  1988cited by this paper
• Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome.

  1988cited by this paper
• Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia.

  1986cited by this paper
• Acetylcholine receptors in the human retina.

  1985cited by this paper
• Visual motor co-ordination and dynamic visual acuity.

  1984cited by this paper
• Antiemetics: neurotransmitter receptor binding predicts therapeutic actions.

  1982cited by this paper
• The cholinergic hypothesis of geriatric memory dysfunction.

  1982cited by this paper
• Evidence for a direct cholinergic involvement in the scopolamine-induced amnesia in monkeys: effects of concurrent administration of physostigmine and methylphenidate with scopolamine.

  1978cited by this paper
• Memory and cognitive function in man

  1977cited by this paper
• Delinquents and the Tapping Test.

  1977cited by this paper
• Studies on human memory: The interactions of diazepam, scopolamine, and physostigmine

  1977cited by this paper
• Human memory and the cholinergic system. A relationship to aging?

  1974cited by this paper
• The Cholinergic Synapse and the Site of Memory

  1971cited by this paper

• Gut–Brain Metabolic Remodeling Mediates the Neuroprotective Effects of Combined Shrimp and Corn Peptides in Scopolamine-Induced Cognitive Impairment

  2026cites this paper
• Anesthetic Amnesia: The Forgotten Importance of Forgetting?

  2025cites this paper
• Scopolamine's Anticholinergic Effects on EEG Spectral, Aperiodic, Complexity, Microstates, and Heart Rate Variability

  2025influential citation
• Interaction adenine-scopolamine in aqueous medium combining experimental spectra with DFT calculations

  2025cites this paper
• Clinical practice guidelines for the prevention and management of postoperative nausea and vomiting (2025 edition)

  2025cites this paper
• Pyridine functionalized nickel(II) N–heterocyclic carbene complexes as highly sensitive molecular sensors for the electrochemical sensing of date rape drugs

  2024cites this paper
• Rhoifolin, baicalein 5,6-dimethyl ether and agathisflavone prevent amnesia induced in scopolamine zebrafish (Danio rerio) model by increasing the mRNA expression of bdnf, npy, egr-1, nfr2α, and creb1 genes.

  2024cites this paper
• Recent findings regarding the synergistic effects of emodin and its analogs with other bioactive compounds: Insights into new mechanisms.

  2023cites this paper
• Neuroprotective Activity of Phytoestrogens Against Scopolamine Induced Oxidative Stress in Mice

  2023cites this paper
• EEG changes as an indication of central nervous system involvement following cyclopentolate 1% eye drops; a randomized placebo-controlled pilot study in a pediatric population

  2023cites this paper
• Update on the sources, pharmacokinetics, pharmacological action, and clinical application of anisodamine.

  2023cites this paper
• In Silico Prediction of Skin Permeability Using a Two-QSAR Approach

  2022cites this paper
• Effects of psychotropic drugs on ocular parameters relevant to traffic safety: A systematic review.

  2022cites this paper
• PARIETAL INTRAHEMISPHERIC SOURCE CONNECTIVITY OF RESTING-STATE ELECTROENCEPHALOGRAPHIC ALPHA RHYTHMS IS ABNORMAL IN NAÏVE HIV PATIENTS.

  2022cites this paper
• Stability analysis of clustering of Norris’ visual analogue scale

  2021cites this paper
• Semimechanistic models to relate noxious stimulation, movement, and pupillary dilation responses in the presence of opioids

  2021cites this paper
• Acute response to cholinergic challenge predicts long‐term response to galantamine treatment in patients with Alzheimer's disease

  2021cites this paper
• A delayed treatment model for the evaluation of scopolamine for VX nerve agent intoxication.

  2021cites this paper
• Biperiden Challenge Model in Healthy Elderly as Proof‐of‐Pharmacology Tool: A Randomized, Placebo‐Controlled Trial

  2021cites this paper
• Pharmacological evidence of a cholinergic contribution to elevated impulsivity and risky decision-making caused by adding win-paired cues to a rat gambling task

  2021cites this paper
• Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug

  2020cites this paper
• Pharmaco-fUS: Quantification of pharmacologically-induced dynamic changes in brain perfusion and connectivity by functional ultrasound imaging in awake mice

  2020cites this paper
• A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4–6 μg/kg) in patients with major depressive disorder

  2020cites this paper
• Endogenous in-session cortisol during exposure therapy predicts symptom improvement: Preliminary results from a scopolamine-augmentation trial.

  2020cites this paper
• Anticholinesterase and Antioxidant Potential of Hydromethanolic Extract of Ziziphus mucronata (Rhamnaceae) Leaves on Scopolamine-Induced Memory and Cognitive Dysfunctions in Mice

  2019cites this paper
• Abnormalities of functional cortical source connectivity of resting-state electroencephalographic alpha rhythms are similar in patients with mild cognitive impairment due to Alzheimer's and Lewy body diseases.

  2019cites this paper
• No synergistic effect of subtherapeutic doses of donepezil and EVP-6124 in healthy elderly subjects in a scopolamine challenge model

  2019cites this paper
• First‐in‐man study of ACT‐709478, a novel selective triple T‐type calcium channel blocker

  2019cites this paper
• Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease

  2019cites this paper
• Sleep deprivation and Modafinil affect cortical sources of resting state electroencephalographic rhythms in healthy young adults.

  2019cites this paper
• Functional Measurements of Central Nervous System Drug Effects in Early Human Drug Development

  2019cites this paper
• Functional Measurements of Central Nervous System Drug Effects in Early Human Drug Development

  2019cites this paper
• Serotonergic and cholinergic modulation of functional brain connectivity: A comparison between young and older adults

  2018cites this paper
• Comparison of scopolamine-induced cognitive impairment responses in three different ICR stocks

  2018cites this paper
• Functional cortical source connectivity of resting state electroencephalographic alpha rhythms shows similar abnormalities in patients with mild cognitive impairment due to Alzheimer's and Parkinson's diseases.

  2018cites this paper
• EEG machine learning for accurate detection of cholinergic intervention and Alzheimer’s disease

  2017cites this paper
• Pharmacokinetics and pharmacodynamics of oral mecamylamine – development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation

  2017cites this paper
• Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study.

  2017cites this paper
• An anti‐nicotinic cognitive challenge model using mecamylamine in comparison with the anti‐muscarinic cognitive challenge using scopolamine

  2017cites this paper
• Time related effects on functional brain connectivity after serotonergic and cholinergic neuromodulation

  2016influential citation
• Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects.

  2016cites this paper
• Why an M1 Antagonist Could Be a More Selective Model for Memory Impairment than Scopolamine

  2016cites this paper
• Measuring blood-brain barrier penetration using the NeuroCart, a CNS test battery.

  2016cites this paper
• The muscarinic antagonists scopolamine and atropine are competitive antagonists at 5-HT3 receptors

  2016cites this paper
• In vivo investigation of antiamnesic effect of Asparagus racemosus root extract in scopolamine induced amnesic mice.

  2015cites this paper
• Neuroprotective Effect of Ellagic Acid Against Chronically Scopolamine Induced Alzheimer ' s Type Memory and Cognitive Dysfunctions : Possible Behavioural and Biochemical Evidences

  2015cites this paper
• Case report: Hyperthermia and diminished consciousness in an elderly woman following an accidental overdose of scopolamine

  2015cites this paper
• Science Is Always Wrong. It Never Solves a Problem without Creating Ten More

  2015cites this paper
• Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.

  2014cites this paper
• Aspects of animal models for major neuropsychiatric disorders

  2014cites this paper
• Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial

  2013influential citation
• Inhibition of central angiotensin converting enzyme ameliorates scopolamine induced memory impairment in mice: role of cholinergic neurotransmission, cerebral blood flow and brain energy metabolism.

  2012cites this paper
• Human pharmacology of current and new treatments for schizophrenia

  2012cites this paper